

## Rcadia Medical Imaging secures first financing round and appoints Hillel Bachrach as COB

**HAIFA, ISRAEL - June 8, 2006** - Rcadia Medical Imaging Ltd., a developer of CAD (Computer Aided Diagnostics) solutions for blood vessel analysis applications focusing on Coronary CT Angiography Diagnostics, announced the closing of a financing round led by 20/20 HealthCare Partners, LLC (20/20HCP).

Rcadia's flagship product, the SmartHeart, is innovative software specially designed to assist radiologists and cardiologists carrying out medical image analysis. SmartHeart automatically segments and locates blood vessels in CT studies, detects and measures calcified plaque, soft plaque, stenosis and aneurysm and maps pathology locations in the coronary tree..

Following the finance round, Rcadia has appointed Hillel Bachrach, Managing Partner at 20/20HCP as its new Chairman of the Board. Other Rcadia's board members include Yossi Morik, Eugene Walach, Dr. Jeffrey Mendel, Mauro Wjunki and Shai Levanon, CEO of Rcadia.

The funds will be used to launch the beta version of the SmartHeart during 2006. The company has already identified leading radiologists to participate as beta sites in the Rcadia study.

Commenting on his appointment to Rcadia's board of directors Dr. Jeffrey Mendel, Chairman of Radiology at Caritas Saint Elizabeth's Medical Center, stated that the growing adoption of CTA either for patients at risk for coronary disease or as part of the increasing demand for the 'triple rule out'(aortic dissection, pulmonary embolism or coronary artery stenosis) in the Emergency Department has created a need for reliable automated segmentation of the coronary vasculature. Smartheart addresses this growing need.

Rcadia was introduced to 20/20HCP through the CJP Boston-Haifa Life sciences Initiative (BHLSI). According to Robin JR Blatt, Project Director, "Our goal is to catalyze strategic collaborations in the life sciences between Boston and Haifa entrepreneurs, executives, investors, researchers and clinicians in academic and corporate settings and to enhance economic growth and development between the 'sister cities'. The successful linkage between Rcadia, which contributes to improvements in biomedical technology and cardiovascular disease detection, and 20/20HCP illustrates the scientific, economic and public health benefits to be gained by leveraging the unique talent and innovation that exists both Israel and Massachusetts."

20/20HCP is a Boston partnership that provides equity financing for promising growth businesses and for buyouts or recapitalizations of established companies specialized in the Medical-Technology industry. 20/20HCP has a unique focus on diagnostic, imaging, and image enhancement on the evolution of diagnostic imaging and personalized medicine.

"We're delighted by the significant support we receive from 20/20 HealthCare Partners LLC." comment Shai Levanon. "Having the financial and commercialization support of a group of industry-leading experts, who share our vision for the development and commercialization of Automatic Computer Aided Detection (CAD) for CT Angiography, is a strong validation of our value proposition and an invaluable asset in achieving a leadership position in the market."